NASDAQ$MASI

Masimo Corp. · Q1 2024 earnings

Q1 2024 earnings · · Investor relations

Briefing

Reported first quarter 2024 financial results.

Masimo's consolidated revenue was $492.8 million, with healthcare revenue at $339.6 million and non-healthcare revenue at $153.2 million. The company reported a GAAP net income per diluted share of $0.35 and a non-GAAP net income per diluted share of $0.77.

  • Consolidated revenue reached $492.8 million.
  • Healthcare revenue amounted to $339.6 million.
  • Non-healthcare revenue totaled $153.2 million.
  • GAAP net income per diluted share was $0.35, while non-GAAP net income per diluted share was $0.77.

Headline financials

Total Revenue

$493M

Previous: $565M-12.8%
EPS

$0.35

Previous: $0.87-59.8%
Capital Expenditures

-$8.2M

Previous: -$8.5M+3.5%
Free Cash Flow

$10.7M

Previous: $12.8M-16.4%
Net Income

$18.9M

Previous: $21.3M-11.3%
Operating Income

$34M

Previous: $38M-10.5%
Gross Profit

$242M

Previous: $285M-15.1%
Cash & Equivalents

$158M

Previous: $174M-9.5%
Total Assets

$2.96B

Previous: $3.12B-5.1%
R&D Expense

$47.8M

No prior period
Stock-Based Comp

$9.6M

Previous: $7.3M+31.5%

Revenue & EPS history

Masimo · Revenue · Quarterly

$493M

Q1 2024-12.8%vs Q1 2023
Beat estimate in 9 of 14 quarters(64%)
ActualEstimate

Forward guidance

Masimo provided estimates for its second quarter 2024 and updated full-year 2024 guidance.

Tailwinds

  • Consolidated revenue is expected to be between $480 million and $510 million for Q2 2024 and between $2,055 million and $2,165 million for the full year 2024.
  • Healthcare revenue is projected to be between $330 million and $340 million for Q2 2024 and between $1,355 million and $1,385 million for the full year 2024.
  • Non-healthcare revenue is anticipated to be between $150 million and $170 million for Q2 2024 and between $700 million and $780 million for the full year 2024.
  • Consolidated operating income is estimated to be between $33 million and $38 million (GAAP) or $67 million and $72 million (Non-GAAP) for Q2 2024.
  • Consolidated earnings per diluted share are expected to be between $0.26 and $0.33 (GAAP) or $0.73 and $0.79 (Non-GAAP) for Q2 2024.

Headwinds

  • The estimates are based on current expectations and are subject to uncertainties and factors that could cause actual results to differ materially.
  • Risks include dependence on Masimo SET® and Masimo rainbow SET™ products, competition, and failure to develop innovative products.
  • The guidance is subject to the company's ability to manage cost structure and the pace of recovery in inpatient volumes.
  • Potential uncertainty during the pendency of any such potential separation that could affect Masimo’s financial performance
  • Negative effects of the announcement or pendency of any such potential separation on the market price of Masimo’s securities and/or on the financial performance of Masimo

Historical earnings impact

How earnings announcements have historically affected this stock's price.

Avg. return before/after earnings

Based on 19 quarterly earnings reports · overlaid with Q1 2024

Historical avgQ1 2024

-0.6%

Avg return

Earnings day

-0.1%

Avg return

5 days after

+1.6%

Avg return

30 days after

54%

35 / 65 earnings

Positive

+17.2%

Q2 2024

Best reaction

-35.8%

Q4 2021

Worst reaction

Earnings price reactions
QuarterReport dateReaction (Day 0)+5 days+30 days
Q1 2026+0.2%+0.1%+0.4%
Q4 2025+0.1%+7.4%+0.6%
Q3 2025-4.8%-3.0%-4.9%
Q1 2025-6.5%+1.3%+6.5%
Q4 2024+12.3%+12.4%-3.5%
Q3 2024+13.7%+10.2%+14.9%
Q2 2024+17.2%+21.1%+9.0%
Q1 2024-13.0%-11.8%-9.6%
Q4 2023-1.5%-3.2%+12.4%
Q3 2023+2.5%+6.6%+30.5%
Q2 2023-4.1%-7.6%-11.8%
Q1 2023-7.0%-8.0%-16.1%
Q4 2022+4.1%+7.9%+5.6%
Q3 2022-12.1%+3.1%+10.1%
Q2 2022+2.1%-0.2%-0.4%
Q1 2022+7.5%+8.5%+19.8%
Q4 2021-35.8%-31.3%-29.9%
Q3 2021+1.4%-0.7%+0.1%
Q2 2021-0.6%+2.3%+3.8%
Q1 2021-6.9%-5.5%-12.4%
Q4 2020+0.5%+0.3%-9.6%
Q3 2020-5.1%-9.0%-0.3%
Q2 2020-7.2%-6.6%-6.7%
Q1 2020-0.6%+1.7%+9.3%
Q4 2019+0.2%-4.5%-14.5%
Q3 2019-1.5%-2.2%+4.7%
Q2 2019-2.8%-7.8%-3.2%
Q1 2019-1.5%+1.1%-2.9%
Q4 2018+1.3%+3.9%+5.5%
Q3 2018-2.2%-3.3%-4.5%
Q2 2018+8.9%+9.1%+18.6%
Q1 2018+4.3%+7.6%+10.2%
Q4 2017+2.2%-1.4%+2.7%
Q3 2017+1.3%-1.0%+2.3%
Q2 2017-10.3%-10.8%-11.5%
Q1 2017-14.2%-17.0%-12.5%
Q4 2016+5.7%+11.1%+21.9%
Q3 2016+5.5%+10.7%+12.3%
Q2 2016+9.3%+6.1%+14.0%
Q1 2016+7.7%
Q4 2015+5.7%
Q3 2015+4.0%
Q2 2015+6.2%
Q1 2015+1.0%
Q4 2014+8.0%
Q3 2014+7.0%
Q2 2014-11.2%
Q1 2014-9.1%
Q4 2013-4.2%
Q3 2013-9.2%
Q2 2013+5.5%
Q1 2013+7.5%
Q4 2012-0.3%
Q3 2012-1.1%
Q2 2012-6.2%
Q1 2012-6.6%
Q4 2009-3.8%
Q4 2011-3.8%
Q3 2011+1.1%
Q2 2011-8.4%
Q1 2011+4.0%
Q3 2010+0.0%
Q2 2010+1.1%
Q4 2010+1.1%
Q1 2010+2.9%

Discussion

Share your read of this quarter. Sign-in carries your eToro identity.

Join the conversation

Sign in with eToro to post your read of this quarter and vote on others'.

Sign in with eToro